anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a glycyrrhizin preparation capable of quickly increasing the concentration of glycyrrhizin in blood by blending glycyrrhizin or salt thereof with a fatty acid glyceride and coating the blend with an enteric coating film. CONSTITUTION:Glycyrrhizin or salts thereof is blended with a fatty acid glyceride (e.g. mono, di or triglyceride of middle chain fatty acid such as stearic acid or caprylic acid) at a ratio of (1:1)-(1:10.0) and the blend is coated with an enteric coating film (e.g. hydroxypropylmethylcellulose phthalate) to provide a glycyrrhizin preparation having a form of tablet, granule, inhalant, capsule, etc. When the preparation is administered, glycyrrhizin is rapidly absorbed in the duodenum or small intestine, because the enteric coating film is dissolved in the duodenum and moved into blood to effectively exhibit the effect. Glycyrrhizin is effective in the therapy of liver disease, allergic disease, etc.
PURPOSE:To provide a remedy for demyelinating diseases such as multiple sclerosis, containing forphenicin as an active component. CONSTITUTION:The objective remedy contains forphenicin of formula as an active component. Forphenicin is an alkaliphostaphase-inhibiting active substance produced by actinomycetes such as Actinomyces fulvoviridis var. acarbodicun MO974-A5 strain (FERM-P No.2015), having immunoregulating action, and expected to be useful for various medical uses. Remarkable crisis-suppressing effect was found by the continuous administration of PBS solution of forphenicin to the abdomenal cavity of experimental allergic encephalitis guinea pig (80% of the guinea pigs survive at a dose of 500mug/head). Dose: 5-300mg daily for man.
Ciprofloxacin tablets, USP (ciprofloxacin hydrochloride) are synthetic antimicrobial agents for oral administration. Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. It is a faintly yellowish to light yellow crystalline substance with a molecular weight of 385.8. Its empirical formula is C17H18FN3O3•HCl•H2O and its chemical structure is as follows:

Ciprofloxacin is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its empirical formula is C17H18FN3O3 and its molecular weight is 331.4. It is a faintly yellowish to light yellow crystalline substance and its chemical structure is as follows:

Ciprofloxacin film-coated tablets are available in 250 mg, 500 mg and 750 mg (ciprofloxacin equivalent) strengths. Ciprofloxacin tablets, USP are white to slightly yellowish. The inactive ingredients are colloidal silicon dioxide, corn starch, hydrogenated vegetable oil, magnesium stearate, microcrystalline cellulose, purified water, sodium starch glycolate. The film-coating suspension (Opadry white 321A180025) contains the following inactive ingredients: glycerol monocaprylocaprate, macrogol (PEG) polyvinyl alcohol graft copolymer, polyvinyl alcohol, talc and titanium dioxide.
The soft tissue mechanical properties can be assessed through elastography and ultrasonography. Both methods can measure passive and active soft tissue properties. These methods are the gold standard to measure stiffness and elasticity, but they are expensive, operator dependent and need a laboratory settings.Recently, myotonometric device has been used to measure the mechanical properties of the muscles and tendons. This method serves many advantages, such as non-invasive, painless and cost-effective. There is an increasing literature on athletic training about how training effects viscoelastic properties. However, to the best of our knowledge, there were no studies assessing stiffness and elasticity of AT, PF and ITB and the relation with ankle mobility in different sport disciplines. The purpose of this study were to demonstrate the mechanical properties of AT, PF and ITB and find out relation with restricted ankle mobility in athletes.
1403062 Burn and scald preparation FERRATON AS 13 Oct 1972 47283/72 Heading A5B A composition for treating burns and scalds comprises an aqueous buffer solution of pH 8-10 including a base, a fatty acid and a surface active agent. The base may be sodium carbonate or an alkali metal hydroxide or phosphate. The fatty acid may be oleic acid. The surface active agent may be sodium lauryl ether sulphate or a sulphonate. The composition may also include diethyl ether. eugenol and chlorophyll.
Nifedipine extended-release tablets are an extended-release tablet dosage form of the calcium channel blocker nifedipine. The product is provided as a general matrix tablet with a polymer coating. Nifedipine is 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester. The molecular formula is C17H18N2O6 and has the structural formula:

Nifedipine is a yellow crystalline substance, practically insoluble in water but soluble in ethanol. It has a molecular weight of 346.3. Nifedipine extended-release tablets contain 90 mg of nifedipine for once-a-day oral administration.

In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, ethylcellulose, hydroxyethyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, titanium dioxide, and triacetin. Contains FD&C Yellow No. 5 (tartrazine) as a color additive.

Nifedipine extended-release tablets meet USP Dissolution Test 7.
Provided by the present invention are an astaxanthin liposome preparation and a preparation method therefor. The astaxanthin liposome is made of egg yolk lecithin, cholesterol, free astaxanthin, and a buffer, the mass ratio of egg yolk lecithin to cholesterol being 6-10: 1, the mass ratio of egg yolk lecithin to free astaxanthin being 120-200: 1, and the solid to liquid ratio of free astaxanthin to the buffer (mg/ml) being 1: 6-10. Further disclosed by the present invention are a method for preparing a liposome that encapsulates free astaxanthin. The liposome that encapsulates free astaxanthin as described in the present invention and the preparation method therefor employ a reverse evaporation method to prepare the free astaxanthin liposome, and employ an ultrasonic probe instrument to carry out ultrasonic treatment until a stable system is obtained. The method may significantly improve the stability of a free astaxanthin liposome. By means of steps such as adjusting the ratio of lipid components to buffer and optimizing ultrasonic processing, the particle size of the liposome may be effectively controlled, and drug loading quantity and encapsulation rate may be increased.
1,221,447. Uracils. E. I. DU PONT DE NEMOURS & CO. 15 Oct., 1968 [16 Oct., 1967], No. 48770/68. Heading C2C. Sodium and potassium salts of 5-chloro-3,6- disubstituted uracils are prepared by reacting an aqueous solution of the sodium or potassium salt of a 3,6-disubstituted uracil with an aqueous solution of a 0-40% stoichiometric excess of sodium or potassium hypochlorite at a temperature between -10 and +65 C. The free uracils may be obtained by acidification of the salts thus produced. The solution of the starting material may be prepared by the reaction of a substituted urea with a #-keto ester in an aprotic solvent followed by alkaline cyclization of the ureido intermediate, or by reacting a substituted acetoacetamide with an alkyl carbamate followed by cyclization of the intermediate crotonamide.
OBJECTIVES: The hourglass like constriction (HGC) of peripheral nerves is a characteristic pathological manifestation of Neuralgic Amyotrophy. Once identified, early surgical intervention is essential. However, the method of surgery is controversial, particularly regarding whether HGC needs to be excised. This study aims to explore the efficacy of early aggressive resection of HGC in the upper limb nerves.
MATERIALS AND METHODS: This retrospective study focuses on 13 nerves of spontaneous upper limb paralysis treated at our hospital from June 2019 to July 2023, in which HGC was identified during surgery. During surgery, epineurectomy and interfascicular neurolysis were performed on the constricted areas. Post-neurolysis, constriction excision was carried out if any of the following conditions were met: (1) A single constriction with constriction ≥75%. (2) Constriction combined with torsion. (3) The presence of ≥2 constrictions. Regular face-to-face follow-ups were conducted postoperatively.
RESULTS: Four cases with a single constriction of less than 75% underwent epineurotomy and interfascicular neurolysis; eight underwent constriction excision, of which four cases with a single constriction and associated torsion had direct end-to-end suturing after excision, and four had more than two constrictions treated with autologous sural nerve grafts. Postoperative follow-ups showed good recovery in all but one case, which had unique pathological features and had underwent only epineurectomy, showing moderate recovery.
CONCLUSIONS: For early surgical treatment of HGCs in peripheral nerves of the upper limbs, if severe constriction, constriction combined with torsion, or the presence of more than two constrictions are identified during surgery, aggressive constriction resection may be a better option.
Adequate nutrition during childhood and adolescence is crucial for proper neurological, musculoskeletal, immunological, and cardiometabolic health and development. Yet, disparities among socially underserved racial/ethnic groups in the United States (US) provide significant challenges to achieving adequate nutrition during these years of rapid growth and maturation. For example, Black children and adolescents are at greater risk for having food insecurity, lower-quality diets, obesity, and numerous associated health challenges that result from these disparities compared to their White peers. A growing body of evidence indicates that improving diet quality is critical for improving childhood and adolescent health and well-being, and that the diverse nutritional profile and bioactive compounds found within dairy foods may play multiple roles in promoting proper growth and development during these life stages. Therefore, to support overall health and development among Black youth, greater education and implementation efforts are needed to help this population meet the national dietary recommendations of 2.5 to 3 servings of dairy foods per day. Continuing to fall short of these recommendations puts Black children and adolescents at risk of multiple nutrient inadequacies and health disparities that can have lifelong impacts on disease development, mental health, and quality of life. This review presents the state of knowledge on health disparities and modifiable nutritional strategies involving milk and dairy foods to support the growth and maturation of children and adolescents, with a special focus on Black youth in the US.
Participants (healthy untrained men and women, age 18-40) start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts.
This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including S. pneumoniae, S. pyogenes, E. faecalis and C. diptheriae are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides, antibodies thereto, and nucleic acids. Assays for compounds which modulate the polypeptides of the present invention for use in therapy are also provided.
The invention relates to a co-crystal of doxetastane, which is a co-crystal of doxetastane and isoniazid, isonicotin, urea or nicotinamide. The invention also relates to a salt of dexrazoxane which is a dexrazoxane salt. The eutectic crystal or the salt of the invention has good stability and is beneficial to long-term storage of the medicine. In addition, the compound has low hygroscopicity and good solubility, is favorable for being used as a pharmaceutical ingredient, and has extremely high pharmaceutical development value. The invention also relates to a preparation method of the eutectic or the salt of the Dedosterx. The preparation method is simple, has good repeatability and is suitable for industrial production.
Group 2 will not conduct the rehabilitative intervetion between T1 and T2. They will start the rehabilitative intervention immediately after the second evaluation (T2) and carry it out for 10 months with remote supervision until the third evaluation meeting (T2).
Treatment may be initiated with a dose of 0.5 mg three times daily. Depending on the response, the dose may be increased at intervals of 3 to 4 days in increments of no more than 1 mg per day. Slower titration to the dose levels greater than 4 mg/day may be advisable to allow full expression of the pharmacodynamic effect of alprazolam. To lessen the possibility of interdose symptoms, the times of administration should be distributed as evenly as possible throughout the waking hours, that is, on a three or four times per day schedule.

Generally, therapy should be initiated at a low dose to minimize the risk of adverse responses in patients especially sensitive to the drug. Dose should be advanced until an acceptable therapeutic response (i.e., a substantial reduction in or total elimination of panic attacks) is achieved, intolerance occurs, or the maximum recommended dose is attained.
Metastasis is the leading cause of cancer-related mortality; however, a complete understanding of the molecular programs driving the metastatic cascade is lacking. Metastasis is dependent on collective invasion-a developmental process exploited by many epithelial cancers to establish secondary tumours and promote widespread disease. The key drivers of collective invasion are "Leader Cells", a functionally distinct subpopulation of cells that direct migration, cellular contractility, and lead trailing or follower cells. While a significant body of research has focused on leader cell biology in the traditional context of collective invasion, the influence of metastasis-promoting leader cells is an emerging area of study. This review provides insights into the expanded role of leader cells, detailing emerging evidence on the hybrid epithelial-mesenchymal transition (EMT) state and the phenotypical plasticity exhibited by leader cells. Additionally, we explore the role of leader cells in chemotherapeutic resistance and immune evasion, highlighting their potential as effective and diverse targets for novel cancer therapies.
This case report describes a 29-year-old man, who was admitted to a psychiatric hospital due to a severe depressive episode without psychotic symptoms. After two weeks he developed acute retrograde autobiographical amnesia. No organic cause was identified, and the patient was therefore diagnosed with dissociative amnesia. The depressive symptoms ceased as the amnesia developed. After five months of follow-up in the outpatient clinic, his amnesia for the time preceding its outbreak remained unchanged. He patient managed to resume a functional daily life.
The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation.

Lorazepam injection, like other injectable benzodiazepines, produces additive depression of the central nervous system when administered with other CNS depressants such as ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants. When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behavior has been observed.

There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.

Marked sedation, excessive salivation, ataxia, and rarely, death have been reported with the concomitant use of clozapine and lorazepam.

Apnea, coma, bradycardia, arrhythmia, heart arrest, and death have been reported with the concomitant use of haloperidol and lorazepam.

The risk of using lorazepam in combination with scopolamine, loxapine, clozapine, haloperidol, or other CNS-depressant drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of lorazepam and these drugs is required.

Concurrent administration of any of the following drugs with lorazepam had no effect on the pharmacokinetics of lorazepam: metoprolol, cimetidine, ranitidine, disulfiram, propranolol, metronidazole, and propoxyphene. No change in lorazepam dosage is necessary when concomitantly given with any of these drugs.
Bedside crossover study of neonates with mild respiratory distress receiving NIPPV. Infants serve as their own controls and are randomized to initial interface of either RAM® infant cannula or Miniflow® nCPAP prongs. Infants are instrumented with the following monitoring equipment: Edi orogastric tube to measure electrical activity of the diaphragm, transcutaneous monitor to measure transcutaneous CO2 and O2, pulse oximeter to measure heart rate and oxygen saturation, and respiratory inductance plethysmography (RIP) bands around the chest and abdomen to measure breathing movements and relative Vt (arbitrary units, a.u.). Data are continuously and simultaneously acquired using a data acquisition system. After 10 minutes of stabilization, infants receive 5 minutes of NIPPV on each of a sequence of four commonly used pressure settings (expressed as peak inspiratory pressure / positive end expiratory pressure): 16/5, 16/8, 20/5, 20/8. This sequence is not randomized and is constant between interfaces. Subjects are then placed on the alternate interface, and the sequence is repeated. Events ("breaths") are separated into 3 types: patient effort synchronized with NIPPV breaths (type I), NIPPV breaths without patient effort (type II), and patient effort without NIPPV breaths (type III).
In highly endemic areas, hepatitis B virus (HBV) infection plays a primary role in the etiology of HCC and is frequently observed in HCC patients. Patients with HBV-related HCC usually have a history of chronic HBV infection. Chemotherapy for other malignancies has been associated with HBV reactivation. Furthermore, in end stage liver disease due to HBV, levels of HBV replication have been correlated with liver function. For TACE, reports on HBV reactivation have been inconsistent. Some studies have demonstrated HBV reactivation, some have not , and others have shown decreased HBV DNA levels . The exact mechanism by which this occurs is still unknown. Although anti-HBV therapy has been reported to suppress HBV reactivation in various clinical settings with immunosuppressive conditions, few reports were concerned with the TACE treatment of HBV-related HCC. Also, the long-term effects of antiviral therapy in relatively advanced HCC patients after HCC remains unclear.

Although it is commonly accepted that antiviral therapy should be commenced before or during HCC treatment if the patients have high viral loads and elevated ALT or total bilirubin values with signs of cirrhosis, the dilemma exists when HBV DNA and liver function (such as ALT, AST, TBIL) remains low level. Therefore, we would call for the establishment of clinical practice guidelines on the antiviral therapy in HBV-related HCC patients, especially a consensus on the indications to administer nucleosides analogs (NAs).

Thus , the purpose of the investigators' study is to prospectively study the efficacy of nucleosides analogs (NAs) in transcatheter arterial chemoembolization for nonresectable hepatocellular carcinoma with relatively low HBV DNA replication and Child-Pugh grade A based on multivariate analysis of prognostic factors. The HBV DNA and liver function parameters will be monitored closely. Once the reactivation occurs in the control group, antiviral therapy would be administered immediately. The study had a interim analysis to allow the trial to be stopped if significant differences were detected. The accumulated data were examined when half patient was enrolled in the clinical trial.
The present invention relates to the fields of molecular virology and immunology. In particular, the invention relates to the use of a non-toxic mutant of diphtheria toxin, CRM197, or a fragment thereof, as an intramolecular adjuvant in a fusion protein to enhance the immunogenicity of a protein of interest (e.g. HEV capsid protein, influenza virus M2 protein, or an immunogenic fragment thereof) fused thereto. The invention also relates to a method for enhancing the immunogenicity of a protein of interest (such as HEV capsid protein, influenza virus M2 protein or an immunogenic fragment thereof), which comprises expressing CRM197 or a fragment thereof in fusion with the protein of interest to form a fusion protein. The invention also relates to a fusion protein comprising CRM197 or a fragment thereof and a protein of interest (e.g., HEV capsid protein, influenza virus M2 protein, or an immunogenic fragment thereof), wherein CRM197 or a fragment thereof enhances the immunogenicity of the protein of interest. The invention also relates to isolated nucleic acids encoding the fusion proteins, constructs and vectors comprising the nucleic acids, and host cells comprising the nucleic acids. The invention also relates to the use of said fusion protein for the preparation of a pharmaceutical composition or a vaccine.
ABSTRACT        The synthesis of useful peptides presents a promising approach to new therapeutic agents. The Dolastatins, a series of linear and cyclic antineoplastic and/or cytostatic peptides isolated from Indian Ocean sea hare Dolabella auricularia represent excellent leads for synthetic modification.        In the present invention, the corresponding amine was allowed to react with Boc-L-phenylalanine.    Synthesis of amides led to excellent yields; The protecting group of amides was removed with hydrogen chloride in acetic acid to afford the hydrochloride salt, The correspondent deprotected N-tert-butyloxycarbonyl-L-phenylalanineamide was coupled with dolaproine in the presence of diethyl phosphorocyanidate and triethylamine thereby yielding dipeptideamides. The protecting groups of amides was removed with trifluoroacetic acid to afford the trifluoroacetate salt. Diethyl phosphorocyanidate was used again with excellent results for coupling tripeptide trifluoroacetate with each of the amide salts to yield Dolastatin 10 structural modifications.        The extraordinary inhibition of cell growth shown by the pentapeptideamides against six major types of human cancer has been presented. The intermediates of these reaction also show anticancer activity against the murine P388 lymphocytic leukemia cell line.